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It is estimated that over 52 million
Americans have at one time used a
prescription drug for a non-medical
reason.
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The use of prescription medications for non-medical reasons is
becoming a serious problem within the United States. Prescription
drug abuse is defined as the use of a medication without a prescription, in a way other than as prescribed, or for the experience
1
or feelings elicited. It is estimated that over 52 million Americans
have at one time used a prescription drug for a non-medical reason. According to the Monitoring the Future (MTF) study, research
by the National Institute on Drug Abuse reports that about one in 12 high school seniors stated they had used a prescription pain
killer in 2010 for non-medical use. The survey also found that prescription painkillers are the most commonly abused drugs among
adolescents. 2 There are several classes of prescription drugs that are commonly abused, including opioids, central nervous system
(CNS) depressants and stimulants. Currently, drug overdose is the second leading cause of accidental death in 16 states. 3

Currently, drug overdose is the second
leading cause of accidental death in
16 states.
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Although it is difficult to accurately measure the current rates of prescription drug abuse, several national organizations have developed methods of doing this through studies and surveys. The results of these studies have varied. The 2010 National Survey on
Drug Use and Health: Summary of National Findings (NSDUH) and MTF use different definitions and questioning strategies to track
the misuse of prescription drugs. 4 Differences aside, both surveys agree that it is a growing problem and the number of people receiving treatment within the past year for misuse of pain relievers more than doubled between 2002 and 2010, from 199,000 to
406,000. A case study from Cardinal Health estimates that one American dies every 19 minutes from an unintentional drug overdose.3 In 2007, the number of overdose deaths from prescription opioids outnumbered deaths from heroin and cocaine combined.
3
These statistics are staggering. When every day approximately 2,500 young people between 12 and 17 years of age abuse a prescription drug for the first time, 5 what are we as pharmacists going to do about this? The recent rise in the number of individuals
abusing prescription drugs has inspired many health care professionals, regulatory agencies and legislators to start doing something about it.
A recent headline story is a prime example of small steps
being made to stop this growing problem. As part of a crackdown on rampant painkiller abuse in Florida, the Drug Enforcement Administration (DEA) charged a health care company and two CVS pharmacies in Sanford, Fla., with violating
their licenses. In the year 2011, the two pharmacies ordered
more than 3 million oxycodone pills, which was 20 times the
6
national average. Officials from the DEA stated that there is
no question that these pharmacies played a role in the
area's prescription drug abuse problem. In recent years, the
DEA has been cracking down on pill mills prescribing patients large amounts of pain pills for no legitimate medical
reasons. It was shocking when a chain pharmacy became
involved and was perpetuating the issue. After their licenses
were suspended, CVS officials stated that they took appro.___ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ___, priate steps with DEA's knowledge to stop filling prescriptions from doctors thought to be prescribing improperly.
"We informed a small number of Florida physicians that CVS/pharmacy will no longer fill the prescriptions they write for Cll narcotics," spokeswoman Carolyn Castel said in a written statement. "Distributions of oxycodone to the two Florida stores have decreased by approximately 80 percent in the last three months compared to the prior three months - we believe in large part due
6
to our action." This is one prominent example of a situation that was allowing prescription drug abuse to flourish, but taking these
actions showed that there are solutions to this problem and positive results were seen.
With the growing problem of prescription drug abuse and misuse,
action has been taken at the federal, state and local level. From
the National Alliance for Model State Drug Laws (NAMSDL) to
state level prescription monitoring programs, these organizations
have developed new ways to help combat this problem.

The NAMSDL is a resource for
legislators, health professionals and
community leaders that are
developing effective state drug and
alcohol laws and policies.

The NAMSDL is a resource for state legislators, health professionals and community leaders that are developing effective state
drug and alcohol laws and policies. The purpose of this organization is to analyze drug and alcohol laws, provide a network of drug
and alcohol experts, and to facilitate building a strong relationship - - - - - - - - - - - - - - - - - - - - - - - '
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between communities, states, and the federal government.
Currently, 21 states are working with the NAMSDL to form and
implement state statutes. Most recently, the NAMSDL has begun
a prescription monitoring initiative. This model law is referred to
as the Model Prescription Monitoring Program Act. The program
was developed to reduce prescription drug abuse and fraud by
creating a tool that physicians can refer to before prescribing a ===~--------===---------=~

Each year, prescription drug abuse
and misuse costs the entire health
insurance industry up to $72.5 billion.

certain drug. In addition, this model law would provide complete confidentiality for prescribers, dispensers, and other health care
professionals to report a potential drug misuse or abuse to a central reporting center. Implementing this model law would provide
8
a resource for law enforcement and regulatory agencies to use and track prescription drug abusers. An advisory committee would
be formed to establish and maintain the prescription monitoring program {PMP) across the nation. Furthermore, this program
would produce an annual report discussing the cost-benefits of the PMP, the impact of the efforts to reduce misuse and abuse of
prescriptions, as well as the number of patients identified through the PMP as addicts and those who then sought treatment. This
report would be submitted to the U.S. Department of Justice {DOJ), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Office of National Drug Control Policy (ONDCP) and be made available to the general public. 8 Each year,
8
prescription drug abuse and misuse costs the entire health insurance industry up to $72.5 billion. The bulk of this cost comes from
hospitalizations. By implementing a prescription monitoring program on a national level, this cost would be reduced greatly.

...__--------=--.. . . . --.

In addition to the NAMSDL working to implement a national PMP, other organizations such as
the Drug Abuse Resistance Education (D.A.R.E.) program and SAMHSA are involved in the
community. These organizations educate teens and adults about the dangers of prescription
drug abuse. By promoting awareness of this problem on a local level, the abuse of medications can be prevented from ever beginning. Most recently, D.A.R.E. has developed a new
9
program called "The Silent Epidemic: Kids and Pharmaceutical Abuse." This initiative teaches
parents about safeguarding their medications and the growing problem of teen prescription
experimentation. In addition to these organizations, many other community programs exist
to target this problem. The American Pharmacist's Association Academy of Student Pharmacists (APhA-ASP) sponsors an outreach initiative for college pharmacy students. The program,
Generation Rx, was created for pharmacy students to teach their local community members
5
about prescription drug abuse. Though developing a nationwide prescription monitoring
program targeting addicts and fraudulent prescriptions would greatly help reduce medication
abuse, education is necessary as well. The implementation of community groups has made a
profound impact locally. Yet, to effectively target this problem, more than just national and
local involvement is required. It is also essential for state legislatures to become involved in
combating prescription drug abuse.

Throughout the nation, 43 states currently have authorized prescription drug monitoring programs (PDMP). Two examples are
Florida and Massachusetts. Both states currently have a PDMP
established. In Florida, health care practitioners are required to
report each time a schedule II, Ill or IV medication is dispensed.
The tool, E-FORCSE was developed in 2009 to help Florida combat
the problem at a state level. 10 This program currently matches the Ohio PDMP. Commonly referred to as OARRS, this system is very
similar to the one Florida has implemented. Massachusetts, on the other hand, has developed a PDMP that targets concentrated
areas of prescription drug abuse. Besides collecting data on scheduled II, Ill, IV and V prescriptions weekly, the PMP Center of Excellence at Brandeis University used in Massachusetts has also developed geospatial data that includes the three most concentrated areas of prescription abuse. Researchers based these areas on the amount of emergency department visits that occur from
11
drug overdose, accidental prescription related death, and the amount of prescriptions that are dispensed from each area. From
these results, researchers were able to identify target areas where prescription monitoring needs to be tightly regulated. Even with
these statewide programs, however, a national database, as suggested by NAMSDL, still needs to be developed. This way, all health
care professionals will be able to monitor patients across the nation. In addition to prescription drug abusers being identified,
fraudulent clinics and pill mills would be exposed as well. Doing so could decrease the number of illegitimate prescriptions written.

43 states currently have authorized
prescription drug monitoring programs

Other than developing prescription drug monitoring programs, legislation is taking other steps toward combating prescription drug
abuse. One example is proper medication disposal. In a national survey conducted by SAMHSA, 70 percent of people who abused
prescription pain relievers got them from a relative or family friend. This is compared to the 5 percent of abusers who obtained
11
pain relievers from Internet sites. These statistics led the DEA to establish drug disposal regulations. Currently, the DEA and other
federal agencies sponsor take-back events. During these events, people can turn over unused prescription and/or over-the-counter
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medications to a law enforcement agency. When take-back days are not available, however, the
FDA promotes proper medication disposal alternatives. To protect the environment and human
health, the FDA no longer recommends flushing prescription medications down the toilet. Instead, medications should be sealed in a plastic bag filled with coffee grounds or kitty litter.
However, certain opioid pain relievers can be life threatening if accidently ingested. Under certain circumstances, the FDA recommends these medications to be flushed. Once the DEA establishes regulations on prescription drug disposal, a public education initiative will be developed to
promote these safe disposal practices. Removing unused prescriptions from the home will further reduce prescription drug abuse. Although the prescriptions are valid and the patient may
not be the abuser, family members and friends still have access to the drugs. Therefore, it is essential to implement prescription drug disposal programs in addition to establishing PDMPs. Together these initiatives will prevent abusers from obtaining prescription substances.

l

Reducing prescription drug abuse requires a combination of federal, state and local action. All
involved in this initiative must understand the areas on which to concentrate their efforts. By
combining patient education with prescription drug monitoring programs and proper drug disposal techniques, the second leading cause of accidental death, prescription drug abuse, can be
.....__ _ _ _ _..... deterred.
One way Ohio is combating the prescription drug abuse problem
is through the Ohio Automated Rx Reporting System (OARRS). It
was created in October 2006, following the passing of legislation
that allowed the Ohio State Board of Pharmacy (OSBOP) to develop a PMP. Pharmacists utilize this program to track the dispensing of any controlled substance or any product which contains tramadol. The data collected in each report includes patient
name, quantity of drug, number of refills, pharmacies the patient
has been filling at and the method of payment of the reported
drug. This drug database allows prescribers, pharmacists and law
enforcement agencies access to prescription history on any patient
receiving reported substances. Every outpatient pharmacy that
dispenses a reported substance to an Ohio resident must submit
the dispensing information to OSBOP through OARRS. Currently,
the rolling data contains 2 years of information that is updated
weekly. 12 According to the OSBOP, OARRS processes almost four
13
thousand requests for reports each day. Most requests are handled within seconds. The ability to easily access these reports has
led to growth of this drug database. Within the past year, there
have been several changes to the Ohio Administrative Code (OAC)
regarding OARRS.

According to the OSBOP, OARRS
processes almost four thousand
requests for reports each day.

.-.======================:::!J.

In an effort to further combat the prescription drug abuse problem through the use of OARRS,
the OSBOP approved a major change in the minimum requirements for the practice of phar14
macy. The new changes to the prospective drug utilization review (OAC 4729 -5-20) require a
pharmacist, at a minimum, to review an OARRS report or another state's report covering a time
~--i.W .J period of at least one year, where applicable and available, if the pharmacist becomes aware of
any of the following:
(1) Receiving reported drugs from multiple prescribers,
(2) Receiving reported drugs for more than twelve consecutive weeks,
(3) Abusing or misusing reported drugs (i.e. over-utilization, early refills, appears overly
sedated or intoxicated upon presenting a prescription for a reported drug, or an unfamiliar
patient requesting a reported drug by specific name, street name, color, or identifying
marks),
(4) Requesting the dispensing of reported drugs from a prescription issued by a prescriber with
whom the pharmacist is unfamiliar (i.e. prescriber is located out-of-state or prescriber is
outside the usual pharmacy geographic prescriber care area),
(5) Presenting a prescription for reported drugs when the patient resides outside the usual
pharmacy geographic patient population.

.
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After the initial report review for a patient, the pharmacist may then exercise professional judgment on determining the frequency
of subsequent requests for OARRS reports or reports from other states. However, if a report is not immediately available, a pharmacist may use professional judgment to determine if filling the prescription is in the best interest of the patient.
These changes significantly affect the minimum requirements for the practice of pharmacy in Ohio. The new rule could fundamentally require an OARRS report to be run on every patient presenting to the pharmacy with a prescription for a reported drug for the
first time. Also, the new rule is vague in discussing when an OARRS report is necessary after an initial report review. Essentially the
new rule could require an OARRS report to be run on every fill for a reported substance. This represents a major change, and potential slow down, in the daily practice of a pharmacy. Additionally, the new rule states that if a pharmacist recognizes any potential problem during a prospective drug utilization review, he/she may be required to review an OARRS report to circumvent or
resolve the problem. In essence, an OARRs report is required for every new prescription for reported substances and it may be required for any subsequent refills.
Although the new rule is certainly well-intentioned and may stop a few instances of prescription drug abuse, it may be lacking in
practicality. Every pharmacist has taken a professional oath to serve the public in an ethical and moral way with the welfare of hu15
manity being a primary concern. In other words, it is expected that a pharmacist should use his knowledge, skills and experience
to combat prescription drug abuse and fraudulent prescriptions, regardless of a law that mandates it. Essentially, OAC 4729-5-20 is
merely a codification of actions that all pharmacists practicing appropriate professional judgment are already taking. The legal
mandating of such actions may also have unintended consequences regarding malpractice liability.

Here is one instance that highlights the ineffectiveness of the rule change:
The current health care system is based on specialization and referrals among physicians, such as primary care
physicians referring patients to a cardiologist, oncologist or endocrinologist. Accordingly, large cities such as
Cleveland or Columbus that have major medical centers get referral patients from all around the state and the
country coming for specialized procedures. Consequently, a large volume of perfectly legitimate prescriptions
for reported substances can be generated from these institutions. Therefore, the pharmacies surrounding these
medical centers will have a substantial amount of perfectly legitimate prescriptions for reported substances
being filled by patients who reside outside the usual geographic patient population of that particular pharmacy.
The new rule change requires that an OARRS report be checked for each of these patients presenting to the
pharmacy, even when there is no indication that the prescription is illegitimate, and often under circumstances
indicating the necessity of the reported substance, i.e. a cancer patient presenting in visible pain. In this example, is the new rule change really an effective way to improve the prescription drug abuse problem? Further,
since the new requirements list actions that professional judgment already dictated, is this really only an
attempt to shift liability and blame to pharmacists as the public becomes more aware of the problem and interested in finding someone to hold accountable?

The new minimum standard not only increases the workload of the pharmacist, but also increases exposure to liability. As discussed above, OAC 4729-5-20 is vague when stating when an
OARRS report is actually required. The vagueness in the new rule
creates the potential for situations to arise where it will not be
clear to the pharmacist whether an OARRS review is required. If
the pharmacist believes that an OARRS review is not required and
does not review OARRS, the pharmacist is taking a risk that other
pharmacists, the OSBOP, or the trier of fact in a malpractice suit
against the pharmacist could conclude that the pharmacist had
failed to meet a minimum requirement for the practice of pharmacy in Ohio. If such a minimum standard is required but not met
in a given case, the potential for a malpractice claim exists because not meeting a statutorily-defined minimum standard of

OARRS is a great system and tool to
be utilized by pharmacists, but
mandating its use through OAC 4 7295-20 may not be the best way to tackle
the prescription drug abuse problem
it is trying to eliminate.
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care imposed on all pharmacists provides strong support for such a claim. Although this by itself is not likely to result in a successful
malpractice suit against a pharmacist, it does provide an opening for a plaintiff to get into court for the matter, which costs time
and money for pharmacists to defend. OARRS is a great system and tool to be utilized by pharmacists, but mandating its use
through OAC 4729-5-20 may not be the best way to tackle the prescription drug abuse problem it is trying to eliminate. While efforts are constantly being developed to combat prescription drug abuse, discussion on whether or not the programs are truly effective continues. There is no simple answer to the prescription drug abuse problem, but the combined efforts of the community,
health care professionals and law enforcement agencies can cooperate to find a solution.
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